Compare · MRNA vs RVMD
MRNA vs RVMD
Side-by-side comparison of Moderna Inc. (MRNA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $34.65B, about 1.4x MRNA ($25.38B).
- Over the past year, MRNA is up 148.9% and RVMD is up 306.6% - RVMD leads by 157.7 points.
- MRNA has been more active in the news (14 items in the past 4 weeks vs 12 for RVMD).
- Both have 25 recent analyst ratings on file.
- Company
- Moderna Inc.
- Revolution Medicines Inc.
- Price
- $63.93+3.46%
- $162.84+3.15%
- Market cap
- $25.38B
- $34.65B
- 1M return
- +39.91%
- +10.42%
- 1Y return
- +148.85%
- +306.59%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 14
- 12
- Recent ratings
- 25
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest MRNA
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
- SEC Form 144 filed by Moderna Inc.
- President Hoge Stephen sold $2,739,870 worth of shares (53,336 units at $51.37) as part of a pre-agreed trading plan and exercised 53,336 shares at a strike of $19.15 (SEC Form 4)
- Moderna to Host Investor Event - Science Day
- Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
Latest RVMD
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.